Spruce Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Lead asset for MPS IIIB shows robust clinical benefit and safety, with regulatory progress supported by FDA engagement and a Q4 BLA submission planned. Commercial strategy targets a rare disease market with strong patient advocacy, and financial runway extends into 2027.
-
FDA engagement has been positive, supporting accelerated approval based on robust biomarker and clinical data, with BLA submission planned for Q4. Commercial and manufacturing strategies are advancing, and financial runway is expected into 2027, with additional funding options available.
-
TA-ERT is advancing toward FDA approval for MPS IIIB, with strong clinical data and a BLA submission planned for late 2024. The therapy shows durable efficacy, a favorable safety profile, and significant market potential, with commercialization strategies focused on specialized centers and global partnerships.
Fiscal Year 2025
-
Announced a new strategy focused on TA-ERT for MPS IIIB, with strong clinical data and FDA alignment for accelerated approval. Financial runway extends through 2025, with additional funding needed for BLA submission and commercialization. Plans target a focused launch and global expansion.
Fiscal Year 2024
-
Upcoming December data from two pivotal studies will inform regulatory and clinical strategy for tildacerfont in CAH, with a focus on steroid reduction and androgenic control. The company is also advancing programs in PCOS and MDD, supported by a strong cash position.
-
Multiple late-stage clinical data readouts for tildacerfont in CAH and PCOS are expected in Q4, with strategic partnerships advancing a precision psychiatry program in MDD. Financial runway extends into 2025, and key decisions on pipeline direction will follow upcoming results.
-
Tildacerfont is advancing in CAH, PCOS, and major depressive disorder, with key data readouts for CAH expected in Q3 and a new phase II depression study starting in Q4. Recent studies show promising biomarker improvements and a strong cash runway through 2025.